OncoTherics CEO, Stefan Ogrodzinski, was one of fifty life science and med tech companies to be selected to pitch at this years Texas Life Science …
Read more
OncoTherics to pitch at the 14th Annual Texas Life Science Forum
The Texas Life Science Forum, co-hosted by BioHouston and Rice Alliance, is the premier life science and healthtech event in Texas that brings together members …
Read more
OncoTherics visits MSKCC and MDAnderson to advance translational programme
OncoTherics’ U.S. clinical translational strategy was advanced this week through discussions with key colleagues at Memorial Sloane Kettering Cancer Centre (New York) and MD Anderson …
Read more
OncoTherics completes first part of DMPK equivalence programme
OncoTherics has successfully completed a sophisticated cross-species in vitro metabolism study designed to evaluate any difference between OCT1004 and its next generation isotopolog OCT1002 in …
Read more
OncoTherics seeks SMART funding to support DMPK programme
After taking expert advice from world class toxicology and DMPK experts, OncoTherics has commenced an innovative DMPK equivalence programme. The close chemical relationship between OCT1002 …
Read more
OncoTherics completes CMC scale up development
GMP scale up development has been completed for OCT1002 and OCT1004. The synthesis route has been re-designed for both assets to ensure ready supply of …
Read more
OncoTherics Poland SA AGM 2023
OncoTherics second annual general meeting was held on 30th June 2023 and the FY2022 audited accounts were approved. The company looks forward to progressing its …
Read more
OncoTherics Poland SA first AGM
OncoTherics held its first AGM as a SPOŁKA AKCYJNA on 29th June 2022 in Warsaw, Poland. The Auditors report was presented alongside the 2021 consolidated …
Read more
Hypoxia-modifier reports encouraging tolerability
ITPP (Myo-lnositol trispyrophosphate) is a natural phosphosugar derivative – well known for its ability to trigger the dissociation of molecular oxygen from haemoglobin. Experimental studies …
Read more
OncoTherics secures 2.32M PLN in private funding
OncoTherics has successfully raised 2.32M PLN in first round funding from founders and Polish investors to leverage 5M PLN of Polish regional grant funding. The …
Read more